The activity of matrix metalloproteinases (MMPs) is a universal feature of cellular invasion, tumor angiogenesis and metastasis, which is counterbalanced and regulated by the natural tissue inhibitors of MMPs (Timps). Here we show that Timp1 gene transfer delivered by an adeno-associated virus (AAV) vector inhibits tumor growth in a murine xenotransplant model. A human Kaposi's sarcoma cell line, forming highly vascularized tumors in vivo and having a high natural permissivity to AAV gene transfer, was transduced to express the Timp1 cDNA. AAV-Timp1-transduced cells secreted high levels of Timp1 that inhibited MMP2 and MMP9 gelatinolytic activity. Following subcutaneous inoculation in nude mice, the AAV-Timp1-transduced cells showed significantly reduced tumor growth when compared to control AAV-LacZ-transduced cells. In addition, direct intratumoral injection of AAV-Timp1 into pre-existing tumors significantly impaired the further expansion of the tumor mass. Histological analyses showed that the AAV-Timp1-transduced tumors had limited development of vascular structures and extensive areas of cell death, suggesting that Timp1 overexpression had an antiangiogenic effect. To further support this conclusion, we demonstrated that AAVTimp1 transduction significantly reduced endothelial cell migration and the invasion of a Matrigel barrier and strongly inhibited angiogenesis in the chick chorioallantoic membrane assay. These results indicate that transfer and overexpression of the Timp1 gene is a promising therapeutic strategy to target tumor-associated angiogenesis in cancer gene therapy.
E xtracellular matrix integrity is maintained by a delicate balance between the synthesis and degradation of its structural components, involving the concerted actions of numerous enzymes, as well as those of specific inhibitors that keep their activity in check. A general aspect of malignancies is a shift of this balance in favor of the proteolysis, promoting cellular proliferation and invasion. Tumor cells can directly secrete proteolytic enzymes or induce the normal neighboring cells to elaborate proteases. 1 In addition to invasion and metastasis, high proteolytic activity also has a crucial role in the induction of tumor angiogenesis, an event that is essential for tumor survival, expansion and dissemination. 2 The members of the matrix metalloproteinases (MMP) family are zinc-dependent proteases that function at neutral pH and collectively degrade most of the proteins in the extracellular matrix. They have been subgrouped into four broad categories, according to their substrate preference and structural similarity: interstitial collagenases, gelatinases, stromelysins and membrane-type MMPs (MT-MMPs). 3, 4 The expression and activity of the MMPs are tightly controlled at several levels. 5 The secreted inactive zymogens must undergo proteolytic cleavage to become catalytically active, and natural inhibitor proteins, such as the tissue inhibitor of metalloproteinases (TIMPs), can block the latent or the active MMPs. 6 Timp1, the first discovered member of the TIMP family, 7 is a glycoprotein that forms an inhibitory complex with a broad spectrum of activated MMPs, including the basement membrane-degrading enzymes MMP2 (gelatinase A, 72-kDa type IV collagenase) and MMP9 (gelatinase B, 94-kDa type IV collagenase). These MMPs have been particularly implicated in tumor progression, regulation of growth factor availability and angiogenesis. 8 The antineoplastic activity of Timp1 has been to date demonstrated in relatively few tumor models following different experimental approaches including transfection, [9] [10] [11] [12] adenovirus gene transfer 13 and retroviral tranduction. 14 The molecular mechanisms by which the antitumoral activity of Timp1 is exerted might involve direct inhibition of tumor cell growth, invasion or tumor angiogenesis.
To investigate the role of Timp1 in modulating tumor cell growth and tumor vessel formation, and to explore the therapeutic potential of Timp1 gene transfer, we exploited an adoptive tumorigenesis model based on tumor formation by KS-IMM cells. This immortal cell line was originally isolated from a Kaposi's sarcoma (KS) lesion 15 and retains most of the properties of KS, including induction of endothelial cell migration and invasion in vitro 16 and strong angiogenic responses in vivo. 17, 18 Inoculation of these cells in nude mice results in the formation of aggressive and highly vascularized tumors that bear a striking resemblance to human KS lesions. These characteristics, coupled with an exquisite permissivity to adeno-associated virus (AAV) vectors, which provide sustained and long-term gene expression, make this cell line an ideal experimental system to assess the role of single factor expression in modulating tumor growth and angiogenesis. We show that Timp1 significantly suppresses tumor growth in vivo and demonstrate that Timp1 negatively regulates the angiogenic process both in vitro and in vivo.
Results

Construction and characterization of AAV-Timp1
To attain a constitutive, high-level expression of Timp1, its cDNA was cloned under the control of the cytomegalovirus (CMV) promoter to obtain the pAAV-Timp1 plasmid, in which the expression cassette is flanked by the AAV inverted terminal repeats (Fig 1a) . This same construct was then used to produce an AAV vector by a standard packaging system based on cotransfection of AAV and adenovirus helper functions. After purification on a CsCl 2 gradient, the viral titer was determined by a competitive PCR assay, as previously described. 19 Similarly, high-titer viral preparations were obtained for AAV vectors expressing the marker genes b-galactosidase (AAV-LacZ) and GFP (AAV-GFP), which were used as control vectors in several experiments.
The expression of human Timp1 in hamster cells was assessed after transfection with the pAAV-Timp1 plasmid or transduction with the recombinant AAV-Timp1 vector. As shown in Figure 1b , in both cases exogenous Timp1 was detected as a 23 kDa polypeptide in the total cell lysates and as a 28 kDa polypeptide in the concentrated cell supernatants of treated cells, indicating that the protein was properly produced, processed, secreted and glycosylated.
To assess the permissivity of KS-IMM cells to AAV vectors, these cells were transduced with a preparation of AAV-GFP and the transduction efficiency was evaluated by flow cytometry. As shown in Figure 1c , these cells were found to be highly sensitive to AAV transduction, without or after treatment with hydroxyurea, an agent that increases AAV infectivity (producing 20 and 63% GFP-positive cells, respectively). 19 After transduction with AAV-Timp1, KS-IMM cells clearly expressed the transgene as shown by immunocytochemistry (Fig 1d) .
Protease inhibitory activity of AAV-Timp1-transduced cells
To visualize the presence of intrinsic gelatinolytic activity produced by the KS-IMM and EAhy.926 cells, serum-free conditioned medium was collected and tested by in vitro zymography (Fig 2a) . Two major areas of proteolysis, corresponding to the molecular weights of MMP9 and MMP2, were observed in KS-IMM cell supernatants. Only the lower band, corresponding to MMP2 activity, was present in EAhy.926 cell supernatants. In both cases, transduction with AAV-Timp1 essentially did not alter the levels of expression and secretion of either MMP. To ascertain the effect of Timp1 on MMP2 and MMP9 activity, reverse zymography was performed using KS-IMM cell supernatants as a source of MMPs. Serum-free media conditioned for 48 hours were collected from Timp1 and mock-transfected 293 cells, concentrated, resolved by gelatin SDS-PAGE and incubated in the presence of KS-IMM supernatant for 16 hours. A clear band at 28 kDa (Fig 2b) , absent in the control lane, showed that AAV-Timp1-transduced cells synthesize and secrete a fully processed recombinant Timp1 that efficiently inhibits gelatinolytic activity.
AAV-Timp1 inhibits tumor growth in vivo
We then investigated whether Timp1 could function as a suppressor of tumor growth of KS-IMM cells in vivo. In an initial set of experiments, KS-IMM cells were transduced with either the AAV-Timp1 or the AAVLacZ vectors, collected as a pool after 48 hours, mixed with Matrigel, and inoculated subcutaneously in nude mice (5 Â 10 6 cells/animal, groups of six animals). In all cases, cell implantation induced the formation of tumors that became evident and palpable after 5 days. However, as shown in Figure 3a , the tumors derived from AAVTimp1-transduced cells grew at a significantly slower rate than control tumors, resulting in an B50% reduction in tumor mass at 5 weeks after cell implantation (0.6170.18 versus 1.1570.27 cm 3 ; Po.01). The histological analysis of tumors recovered upon termination of the experiment showed that tumors from AAV-Timp1-transduced cells exhibited clear signs of regression, such as limited development of vascular structures and extensive areas of cell death (Fig 3b) . In contrast, the control KS-IMM tumors transduced with AAV-LacZ showed massive proliferation of spindle-shaped cells and the presence of numerous blood vessels, with the formation of vascular lacunae and erythrocyte extravasation.
These data clearly indicated that the transduction of KS-IMM cells with AAV-Timp1 represents an efficient method to impair the growth of this kind of tumor. To explore possible therapeutic potentials of this vector in cancer gene therapy, we performed a second set of experiments, in which we injected established KS-IMM xenograft tumors with either the AAV-Timp1 or the Antitumoral effect of AAV-Timp1 S Zacchigna et al AAV-LacZ vectors. The experimental design for these experiments is shown in Figure 4a . The intratumoral injection of AAV-Timp1 induced marked growth suppression and initial regression of the tumors, particularly evident after the last vector injection on day 21 (tumor mass fold increase 9.174.2 versus 4.072.0 fold for the AAV-LacZ-and AAV-Timp1-transduced tumors, respectively, at day 35; Po.05; Fig. 4b ). The long-term effect of AAV-Timp1 injection is likely to be due to the delayed appearance of transgene expression after AAV gene transfer. Similar to the inoculation of in vitro-transduced cells, histological analysis of the tumors showed massive KS-IMM cell proliferation interspersed with many blood vessels in the AAV-lacZ-injected tumors. In contrast, the tumors treated with AAV-Timp1 presented large necrotic areas and numerous inflammatory cells (Fig 4c) .
Timp1 inhibits cell migration across a basement membrane
The histology of the tumors described above, together with the biological and clinical hallmarks of KS, suggested that the inhibition of tumor growth by Timp1 could be largely due to a direct repression of tumor angiogenesis. Therefore the capacity of Timp1 to modulate the endothelial response to angiogenic factors in vitro was investigated in the chemoinvasion assay. Previous studies have shown that KS-IMM cells release several chemoattractants and angiogenic factors, including VEGF and b-FGF, which stimulate the motility and invasiveness of endothelial cells. 20, 21 The EAhy.926 cells produce a gelatinase activity at 72 kDa, corresponding to MMP2 (Fig 2a) , whose activity is important in angiogenic growth factor-induced invasion. 22 To ascertain the effect of Timp1 overexpression on endothelial cell migration through a reconstituted basement membrane, the supernatant harvested from transfected 293 cells, which contains Timp1 activity (Fig 2b) , was added to EA.hy926 cells in the upper compartment of invasion chambers. After a 1-hour incubation, chemoattractants were placed in the lower compartment. This preincubation had no significant effect on the adhesion of the cells to the Matrigel (not shown). However, this treatment significantly reduced (P ¼ .026) the ability of the endothelial cells to invade and migrate across the Matrigel barrier (Fig 5) .
This finding indicates that the levels of Timp1 expressed by AAV-transduced KS-IMM cells significantly interfere with the invasive capacity of endothelial cells, suggesting that the biological effects of Timp1 gene transfer extend beyond the cells actually producing the factor.
Antiangiogenic activity of AAV-Timp1
To examine whether the inhibitory activity of Timp1 on endothelial cell migration might directly affect angiogenesis, we set up a chick chorioallantoic membrane (CAM) assay, using 50 ng of recombinant VEGF as a proangiogenic stimulus. Transduced cells (3 Â 10 4 ) were seeded on a foamy sponge on top of the CAM of chick eggs, and the extent of the new developing vasculature was assessed by microscopic inspection. The presence of control rhVEGF induced the development of new blood vessels sprouting in a radial pattern around the sponge and frequently 
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S Zacchigna et al penetrating into it. Seeding of mock-transduced cells on the sponge did not interfere with this effect (Fig 6a) . In contrast, no blood vessels penetrated the sponges in which AAV-Timp1-transduced cells had been seeded. Instead, developing vessels seemed to turn away from the sponge, forming arc-like structures as indicated by the arrows in Figure 6b . Furthermore, some vessels close to the sponge exhibited degenerative features, such as irregular morphology and several interruptions (shown in the higher magnification inset). These observations clearly indicate that secretion of Timp1 by AAV-Timp1-transduced cells is able to markedly impair the angiogenic process.
Discussion
In this study, we show that overexpression of Timp1 represses tumor growth in an animal model of adoptive tumorigenesis based on KS-IMM cell implantation in nude mice. A significant therapeutic effect was obtained either by transduction of cultured cells before implantation or by direct injection into pre-existing tumors. Timp1 gene transfer was obtained by exploiting the high sensitivity of the KS-IMM cells, higher than that observed with other cell types under the same conditions, to infection with AAV vectors. In contrast to other gene delivery systems, the expression of genes delivered by AAV vectors is not subjected to progressive silencing over time in vivo. As a consequence, these vectors offer the unique possibility to study the biological and therapeutic effects of factor expression and release in experimental animal models over relative long periods of time. [23] [24] [25] Furthermore, cells transduced with AAV do not express any viral proteins and thus do not become immunogenic or elicit inflammatory responses. This might be crucial in a clinical setting, and, in particular, in cancer gene therapy, where prolonged expression of the therapeutic gene might be required in order to achieve a therapeutic response.
MMPS are involved in a wide range of phenomena associated with tumor progression. 4 In addition, a growing body of evidence indicates that endogenous inhibitors of MMPs exert biological effects that extend beyond the inhibition of MMP enzymatic activity, being able to affect directly basic cellular functions, such as proliferation and survival. 14, 26 In our model, the histology of AAV-Timp1-transduced tumors revealed several signs of regression, including the presence of cells with picnotic nuclei, suggesting that Timp1 overexpression could have a direct proapoptotic activity on the tumor cells in vivo. However, we did not observe differences in either the growth rate or the apoptotic death rate of Timp1-expressing KS-IMM cells as compared to controls (not shown), indicating that Timp1 did not affect KS-IMM cell survival in vitro. It appears that Timp1 causes tumor cell death and tumor growth inhibition in vivo indirectly, most probably through the inhibition of angiogenesis. Previous studies have shown divergent effects of Timp1 overexpression in EBV-negative Burkitt's lymphoma: an initial antiapoptotic effect stimulating tumor growth, followed by an antiangiogenic effect that caused tumor regression.
14 New blood vessel formation is a hallmark of solid tumor progression, since both local expansion and metastatic dissemination depend on vascularization of the primary tumor mass. Among human tumors, KS shows an impressively abundant neovascularization, Antitumoral effect of AAV-Timp1 S Zacchigna et al accompanied by spindle-shaped cell growth, inflammation and edema. The pathogenesis of KS has long been debated, but several lines of evidence suggest that KS most probably develops from reactive endothelial cells as a result of a ''hit and run'' mechanism of the KSassociated herpesvirus HHV8 producing uncontrolled angiogenic factor release and inflammation. 27 KS-IMM cells display a strong angiogenic activity, and the tumors they generate show tumor cell proliferation and vascular structure formation, probably due to massive endothelial cell recruitment. 21 Our experiments provide two-fold evidence of the specific antiangiogenic potential of Timp1. First, Timp1 was able to inhibit significantly endothelial cell migration in response to the angiogenic factors secreted by KS-IMM cells in the chemoinvasion assay. Second, Timp1 had a profound effect on new blood vessel development in the CAM assay, an established in vivo assay measuring angiogenesis. Thus, Timp1 inhibition of angiogenesis and host endothelial cell recruitment might represent a primary mechanism of the inhibition of KS tumor growth.
Blocking endothelial cell invasion is the basis of several current antiangiogenic and antitumor therapies. 28, 29 Endothelial cells invasion requires the degradation of the basement membrane by MMP2 produced by endothelial cells themselves in response to angiogenic factors. MMP2 is known to be highly expressed in human KS and other tumors, 30 substantially contributing to tumor cell invasion and dissemination into tissues. Our experiments confirm secretion of MMP2 by endothelial cells and show that this metalloproteinase is also constitutively produced by KS-IMM cells, thus possibly contributing to direct tumor expansion and invasion of these cells in vivo.
The concept of inhibiting MMP activity for cancer treatment is a very attractive one given the broad involvement of these enzymes in most steps of tumor cell biology, including tissue invasion, metastasis and induction of angiogenesis. The hopes raised by small synthetic MMP inhibitors were dashed by poor performance in most clinical trials, which disclosed the existence of several drawbacks associated with enzyme specificity, drug delivery and stability, and the occurrence of serious side effects. 31 More important may be the timing of administration of the different inhibitory drugs. 4, 32 The possibility to obtain better therapeutic efficacy by Timp1 gene transfer and overexpression might provide several advantages as compared to systemic drug administration. Among these advantages, our in vivo data underscore the possibilities to achieve a higher local concentration of the therapeutic molecule through direct intratumoral administration, thus avoiding serious side effects at distant sites, and to obtain sustained and prolonged expression of this molecule by single gene administration.
Materials and methods
Cell cultures
The human Eahy.926 cells, of endothelial origin, were derived from the fusion of human umbilical vein endothelial cells with the A549 carcinoma cell line, 33 and still retain endothelial characteristics. 34 KS-IMM is an immortalized cell line derived from a human KS lesion, which forms highly vascularized tumors in vivo. 15 Human HEK 293 and hamster CHO cells were purchased from the American Type Culture Collection, Manassas, VA. All cells were cultured in D-MEM, supplemented with 10% FCS, 100 U/ml penicillin, 100 mg/ml streptomycin, and maintained at 371C under a mixture of 95% air and 5% CO 2 .
Western blotting for Timp1
To analyze Timp1 levels in cell-associated and conditioned media fractions, cells were washed after infection with AAV-Timp1 and maintained in serum-free media for 24 hours. Conditioned media were collected and concentrated using Centricon-10 filter units (Amicon, Inc., Stonehouse). Immunoreactive proteins were visualized using the mouse monoclonal antibody 102D1 against Timp1 (NeoMarkers, Fremont, CA) and a chemiluminescence assay (ECL, Amersham Pharmacia Biotech, Little Chalfont).
Zymography and reverse zymography
KS-IMM and Eahy.926 total cell lysates were harvested and used for substrate gel electrophoresis. Samples were normalized for protein content and resolved in nonreducing conditions on a 0.1% gelatin (Sigma Chemical Co., St Louis, MO) and 12% SDS-polyacrylamide gel. After electrophoresis, the gel was washed at room temperature for 30 minutes in 2.5% Triton X-100 to remove SDS and incubated for 16 hours at 371C with shaking in the developing buffer (50 mM Tris-HCl, pH 7.4, 10 mM CaCl 2 and 0.05% Brij 35). The gel was stained in 0.1% Coomassie brilliant blue. Clear zones against the blue background indicate the presence of gelatinolytic activity.
Functional activity of secreted Timp1 was assessed by reverse gel zymography. 293 cells transfected with pAAVTimp1 were cultured for 24 hours in serum-free D-MEM and culture supernatants were harvested, filtered, concentrated by ultrafiltration through Centricon-10 filter units (Amicon, Inc., Stonehouse) and loaded onto a 0.2% gelatin and 12.5% SDS-polyacrylamide gel. The gel was then incubated for 16 hours in the supernatant from KS-IMM cells, used as a source of MMPs. Functional Timp1 appeared as a dark band at approximately Mr 28,000.
Matrigel invasion assay
To visualize and quantify cellular invasion, 1 Â 10 5 Eahy.926 cells were incubated for 1 hour in conditioned medium from Timp1-or mock-transfected cells and seeded in the upper chamber of 8 mm pore size 24-well plate invasion chambers coated with Matrigel Matrix (Biocoat Matrigel Invasion Chamber, Becton Dickinson, San Jose, CA). Supernatant from KS-IMM cells, which contains numerous chemoattractants, was placed in the lower compartment of the chamber. After 24 hours, the cells on the upper surface of the filter were removed by Antitumoral effect of AAV-Timp1 S Zacchigna et al gentle scraping with a cotton bud, whereas those that had migrated to the lower side were fixed in methanol and stained with Giemsa solution. Five random 400 Â fields were counted per section. Each sample was performed in triplicate. Data are presented as mean number of invaded cells/400 Â field.
Chick embryo chorioallantoic membrane assay
CAMs of fertilized chicken eggs were maintained at 371C. On day 3 of incubation, 2 ml of albumin was removed to detach the developing CAM from the shell and an oval window was opened in the upper side of the shell. After 5 days, 5 ml of AAV-Timp1-or mock-transduced CHO cells, together with 50 ng of recombinant hVEGF, were loaded onto 1 mm 3 gelatin sponges (Gelfoam; PharmaciaUpjohn, Kalamazoo, MI), previously applied onto the top of the CAM. Sponges adsorbed with wt CHO cells and hVEGF alone were used as negative and positive controls respectively. CAMs were examined daily under a stereomicroscope and photographed at day 12, when the angiogenic response peaked.
AAV vectors
The rAAV vector used in this study is based on the pTR-UF5 construct that was kindly provided by N Muzyczka (University of Florida, Gainesville, FL), which expresses the GFP gene under the control of the human CMV immediate early promoter. The coding sequence of the human Timp1 cDNA was obtained by RT-PCR amplification and cloned in the vector to substitute the GFP and neomycin-resistance genes. Cloning and propagation of AAV plasmids was carried out in the JC 8111 Escherichia coli strain. Infectious AAV2 vector particles were generated in 293 cells, cultured in 150 mm-diameter Petri dishes, by cotransfecting each plate with 15 mg of each vector plasmid together with 45 mg of the packaging/ helper plasmid, pDG (kindly provided by JA Kleinschmidt, Heidelberg, Germany), expressing AAV and adenovirus helper functions. Viral stocks were obtained by CsCl 2 gradient centrifugation as previously described. 19, 35 rAAV titers were determined by measuring the copy number of viral genomes in pooled, dialyzed gradient fractions using a competitive PCR procedure with primers and competitors mapping in the CMV promoter region common to all vectors. 19 The titers of all the viral preparations used in this study were in the range between B1 Â 10 12 and B1 Â 10 13 particles/ml. The efficiency of transduction of KS-IMM cells by AAV vectors was evaluated with or without overnight treatment with 1 mM hydroxyurea, an agent that increases transduction of different cell types. 19 
Flow cytometry
Flow cytometric analysis of GFP-expressing cells after transduction with AAV-GFP was performed on a FACScalibur (Becton Dickinson, San Jose, CA) instrument acquiring 1 Â 10 4 events for each sample.
Immunocytochemistry
Protocols for immunocytochemistry were according to the Vectastain Elite ABC Kit (universal or goat) from Vector Laboratories using an antibody against Timp1 from NeoMarkers, Fremont, CA. After treatment, slides were rinsed in PBS and signal was developed using 3,3 0 -diaminobenzidine as substrate for the peroxidase chromogenic reaction (Lab Vision Corporation, Fremont, CA).
Tumor growth in vivo
Animal care and treatment were conducted in conformity with institutional guidelines in compliance with national and international laws and policies (EEC Council Directive 86/609, OJL 358, December 12, 1987) . In a first set of experiments, after 48 hours transduction with the AAV-Timp1 and AAV-LacZ vectors, 5 Â 10 6 KS-IMM cells were resuspended in Matrigel (10 mg/ml) and injected subcutaneously in the flanks of healthy nude (nu/nu) mice (six animals per group). In a second set of experiments, to measure the therapeutic potential of AAV-Timp1 into established tumors, 4 Â 10 6 KS-IMM cells resuspended in Matrigel were injected into the subcutaneous tissue of nude (nu/nu) mice (five animals per group). After 1 week, intratumoral injections of AAVTimp1 or AAV-LacZ (5 Â 10 11 viral particles) were performed every second day, three times. An additional administration of each vector was performed on day 21, when the tumors became substantially larger, thus allowing easier injection into the center of the tumor mass and, most likely, the transduction of a greater number of cells. Tumor size was measured over time with a caliber following standard procedures. After 35 days, the animals were killed and tumor specimens were taken from the injection sites. Each sample was fixed in formalin, embedded in paraffin, sectioned and histologically analyzed by hematoxylin and eosin staining.
Statistical analysis
Statistical analysis was performed with a nonparametric Mann-Whitney test to compare variables between groups using the StatView 4.5 statistical software package for Macintosh (Abacus Concepts, Berkeley, CA).
